Erwin Dreesen

2.5k total citations
102 papers, 1.5k citations indexed

About

Erwin Dreesen is a scholar working on Genetics, Immunology and Epidemiology. According to data from OpenAlex, Erwin Dreesen has authored 102 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Genetics, 46 papers in Immunology and 43 papers in Epidemiology. Recurrent topics in Erwin Dreesen's work include Inflammatory Bowel Disease (50 papers), Microscopic Colitis (27 papers) and Immunodeficiency and Autoimmune Disorders (27 papers). Erwin Dreesen is often cited by papers focused on Inflammatory Bowel Disease (50 papers), Microscopic Colitis (27 papers) and Immunodeficiency and Autoimmune Disorders (27 papers). Erwin Dreesen collaborates with scholars based in Belgium, Netherlands and United States. Erwin Dreesen's co-authors include Séverine Vermeire, Ann Gils, Marc Ferrante, Gert Van Assche, Isabel Spriet, Griet Compernolle, Bram Verstockt, Matthias Gijsen, Zhigang Wang and Ruth Van Daele and has published in prestigious journals such as SHILAP Revista de lepidopterología, Gastroenterology and Advanced Drug Delivery Reviews.

In The Last Decade

Erwin Dreesen

90 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Erwin Dreesen Belgium 21 913 733 603 214 214 102 1.5k
Akihiro Yamada Japan 22 558 0.6× 463 0.6× 226 0.4× 522 2.4× 38 0.2× 73 1.5k
Henit Yanai Israel 28 1.8k 2.0× 1.3k 1.8× 600 1.0× 923 4.3× 19 0.1× 125 2.6k
Fabio Salvatore Macaluso Italy 23 428 0.5× 1.1k 1.5× 186 0.3× 256 1.2× 21 0.1× 96 1.8k
Jean Frédéric Colombel France 12 1.6k 1.7× 1.2k 1.7× 331 0.5× 690 3.2× 60 0.3× 14 2.2k
Stefanie Howaldt Germany 13 364 0.4× 264 0.4× 121 0.2× 183 0.9× 40 0.2× 31 1.2k
Helena Tavares de Sousa Portugal 13 904 1.0× 658 0.9× 232 0.4× 320 1.5× 17 0.1× 39 1.2k
Michael Chiorean United States 21 747 0.8× 630 0.9× 219 0.4× 850 4.0× 23 0.1× 94 1.9k
Tae Oh Kim South Korea 22 274 0.3× 282 0.4× 102 0.2× 568 2.7× 83 0.4× 133 1.5k
Anita Afzali United States 18 505 0.6× 552 0.8× 320 0.5× 295 1.4× 15 0.1× 84 1.1k
Giorgia Bodini Italy 26 556 0.6× 653 0.9× 153 0.3× 1.1k 5.3× 21 0.1× 112 2.1k

Countries citing papers authored by Erwin Dreesen

Since Specialization
Citations

This map shows the geographic impact of Erwin Dreesen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erwin Dreesen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erwin Dreesen more than expected).

Fields of papers citing papers by Erwin Dreesen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erwin Dreesen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erwin Dreesen. The network helps show where Erwin Dreesen may publish in the future.

Co-authorship network of co-authors of Erwin Dreesen

This figure shows the co-authorship network connecting the top 25 collaborators of Erwin Dreesen. A scholar is included among the top collaborators of Erwin Dreesen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erwin Dreesen. Erwin Dreesen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Wang, Zhigang, et al.. (2025). A Risk Stratification Tool for Relapse After Intravenous-To-Subcutaneous Switching of Infliximab in Patients With Inflammatory Bowel Diseases. The American Journal of Gastroenterology. 121(1). 179–186.
3.
Verstraete, Esther, Erwin Dreesen, Koen Schruers, Siska Desplenter, & Chris Bervoets. (2025). High Doses of Antidepressants and Long-term Treatment of Obsessive-compulsive Disorder: Another Barrier to Accessing Deep Brain Stimulation?. ALPHA PSYCHIATRY. 26(5). 41734–41734.
4.
Dreesen, Erwin, Matthias Gijsen, Stefanie Desmet, et al.. (2024). Decreased Kidney Function Explains Higher Vancomycin Exposure in Older Adults. Drugs & Aging. 41(9). 753–762. 1 indexed citations
5.
Wauters, Joost, Yves Debaveye, Bart Rijnders, et al.. (2024). Dosing of IV posaconazole to treat critically ill patients with invasive pulmonary aspergillosis: a population pharmacokinetics modelling and simulation study. Journal of Antimicrobial Chemotherapy. 79(7). 1645–1656.
6.
Laenen, Annouschka, Pieter Vermeersch, Glynis Frans, et al.. (2024). Human serum albumin: prediction model and reference values for preterm and term neonates. Pediatric Research. 99(2). 604–611. 1 indexed citations
7.
Alsoud, Dahham, Dirk Jan A. R. Moes, Zhigang Wang, et al.. (2024). Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Therapeutic Drug Monitoring. 46(3). 291–308. 8 indexed citations
8.
Dreesen, Erwin, Thomas Vanassche, Peter Verhamme, et al.. (2023). Insights into the Pharmacokinetics and Pharmacodynamics of Direct Oral Anticoagulants in Older Adults with Atrial Fibrillation: A Structured Narrative Review. Clinical Pharmacokinetics. 62(3). 351–373. 8 indexed citations
9.
Wicha, Sebastian G., Debby Thomas, Ilse Hoffman, et al.. (2023). A Model-Based Tool for Guiding Infliximab Induction Dosing to Maximize Long-term Deep Remission in Children with Inflammatory Bowel Diseases. Journal of Crohn s and Colitis. 17(6). 896–908. 19 indexed citations
10.
11.
Gijsen, Matthias, Pieter Annaert, Ruth Van Daele, et al.. (2022). Meropenem Target Attainment and Population Pharmacokinetics in Critically Ill Septic Patients with Preserved or Increased Renal Function. SHILAP Revista de lepidopterología. 18 indexed citations
12.
Outtier, An, Sebastian G. Wicha, Alexander Kensert, et al.. (2022). Multi‐model averaging improves the performance of model‐guided infliximab dosing in patients with inflammatory bowel diseases. CPT Pharmacometrics & Systems Pharmacology. 11(8). 1045–1059. 20 indexed citations
13.
Daele, Ruth Van, Joost Wauters, Erwin Dreesen, et al.. (2022). Exposure to intravenous posaconazole in critically ill patients with influenza: A pharmacokinetic analysis of the POSA‐FLU study. Mycoses. 65(6). 656–660. 6 indexed citations
14.
Daele, Ruth Van, Yves Debaveye, Robin Vos, et al.. (2021). Concomitant use of isavuconazole and CYP3A4/5 inducers: Where pharmacogenetics meets pharmacokinetics. Mycoses. 64(9). 1111–1116. 3 indexed citations
15.
Verstockt, Bram, Dahham Alsoud, Triana Lobatón, et al.. (2021). The effect of aging on infliximab exposure and response in patients with inflammatory bowel diseases. British Journal of Clinical Pharmacology. 87(10). 3776–3789. 8 indexed citations
16.
Wang, Zhigang, et al.. (2021). Recent advances in clearance monitoring of monoclonal antibodies in patients with inflammatory bowel diseases. Expert Review of Clinical Pharmacology. 14(12). 1455–1466. 19 indexed citations
17.
Hanžel, Jurij, Gregor Novak, Borut Štabuc, et al.. (2021). Ustekinumab Dosing Individualization in Crohn’s Disease Guided by a Population Pharmacokinetic–Pharmacodynamic Model. Pharmaceutics. 13(10). 1587–1587. 17 indexed citations
18.
Hanžel, Jurij, Gregor Novak, Borut Štabuc, et al.. (2020). Peak Concentrations of Ustekinumab After Intravenous Induction Therapy Identify Patients With Crohn’s Disease Likely to Achieve Endoscopic and Biochemical Remission. Clinical Gastroenterology and Hepatology. 19(1). 111–118.e10. 32 indexed citations
19.
Verstockt, Bram, Erwin Dreesen, Maja Noman, et al.. (2019). Ustekinumab Exposure-outcome Analysis in Crohn’s Disease Only in Part Explains Limited Endoscopic Remission Rates. Journal of Crohn s and Colitis. 13(7). 864–872. 80 indexed citations
20.
Dreesen, Erwin, Filip Baert, David Laharie, et al.. (2019). Monitoring a Combination of Calprotectin and Infliximab Identifies Patients With Mucosal Healing of Crohn’s Disease. Clinical Gastroenterology and Hepatology. 18(3). 637–646.e11. 60 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Akihiro Yamada Breakdown of academic impact, for papers by Henit Yanai Breakdown of academic impact, for papers by Fabio Salvatore Macaluso Breakdown of academic impact, for papers by Jean Frédéric Colombel Breakdown of academic impact, for papers by Stefanie Howaldt Breakdown of academic impact, for papers by Helena Tavares de Sousa Breakdown of academic impact, for papers by Michael Chiorean Breakdown of academic impact, for papers by Tae Oh Kim Breakdown of academic impact, for papers by Anita Afzali Breakdown of academic impact, for papers by Giorgia Bodini
Rankless by CCL
2026